Cargando…
Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy
BACKGROUND: To evaluate the quantitative changes of retinal pigment epithelial (RPE) atrophy during 3-year follow-up period of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV). METHODS: We retrospectively reviewed consecutive 100 Japanese patients with unilateral symptomatic treat...
Autores principales: | Hikichi, Taiichi, Kitamei, Hirokuni, Shioya, Shoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868043/ https://www.ncbi.nlm.nih.gov/pubmed/27184489 http://dx.doi.org/10.1186/s12886-016-0237-x |
Ejemplares similares
-
Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy
por: Hikichi, Taiichi, et al.
Publicado: (2013) -
Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy
por: Hikichi, Taiichi
Publicado: (2015) -
Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014) -
Intraoperative endoscopic observation of sclerotomy site after cannula removal for 23-gauge vitrectomy
por: Hikichi, Taiichi, et al.
Publicado: (2014) -
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
por: Gu, Xiaoya, et al.
Publicado: (2019)